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Further evidence from Iran that rapid withdrawal from opioids under anaesthesia followed 
by the opioid-blocking drug naltrexone can work for highly motivated caseloads with 
copious 'recovery capital'. For others this expensive and when not adequately controlled, 
potentially risky procedure generally ends in overdose-threatening relapse.
Summary Ultra-rapid opiate detoxification typically involves a day or two of 
hospitalisation during which patients dependent on opiate-type ('opioid') drugs like heroin 
are anaesthetised or deeply sedated while the opiate-blocking drug naloxone is 
administered by infusion in to the blood stream to precipitate sudden withdrawal. Then 
patients are started on prescriptions of naltrexone tablets which (as long as they are 
taken) continue to block the effects of opiate-type drugs, an attempt to prevent the 
relapse to regular opioid use which commonly follows withdrawal.
For the featured study records were analysed of 45 male patients admitted for such 
procedures between 2003 and 2005 to a surgical centre's department of anaesthesiology 
in Iran's capital Tehran. They were selected to be free of dependence on other drugs or 
alcohol except for cannabis, and free of severe physical or mental illness which might 
contraindicate general anaesthesia. For this and for other reasons they were relatively 
well placed to overcome their dependence via an abstinence-oriented route. Forty of the 
45 were addicted to opium and just five injected. On average in their early 30s, they 
were committed to abstinence and had good family support. Over half were married and 
nearly 80% employed. They were attending an expensive private hospital so came 
predominantly from wealthy families, who (in the absence of a public welfare support 
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system) can exert considerable pressure on opiate-dependent relatives, as can wives for 
whom such dependence is grounds for divorce. Also, in Iran familial solidarity is highly 
developed and can provide a high level of support and motivation for abstinence-oriented 
patients.
On admission patients were detoxified by means of a six-hour infusion of naloxone under 
general anaesthesia; medications used were midazolam, propofol, clonidine and the 
muscle relaxant atracurium. For 24 hours after patients woke staff documented severity 
of withdrawal on a standard checklist of physical signs such as runny noses, sweating, 
cramps and dilated pupils.
Usually discharge was scheduled for the day after detoxification. Then naltrexone (50mg/
day) was prescribed for nine months with assessments every four weeks by a clinician 
with extensive experience in the treatment of dependence. At these consultations, 
naltrexone was re-prescribed and the patient's progress monitored, verified with the 
patients' agreement by talking to their families. For the purposes of the study, patients 
who missed these visits were considered relapsed.
Main findings
All the patients were successfully detoxified during inpatient stays of two days (one 
night) for all but two, who stayed three days. Withdrawal signs after awakening peaked 
within one to three hours but were generally few and mild, consisting universally of 
dilated pupils plus typically one other symptom. Severe symptoms were observed only in 
two patients, one an injector and the other dependent on cannabis as well as opioids. 
There were no serious adverse events, but there was one case of prolonged 
unconsciousness, eight of mild and transient confusion, and six of depressed mood. 
Monitored cardiopulmonary signs were stable during the whole treatment in all patients.
Of the 45, 36 (80%) continued naltrexone therapy and reported relapse-free status for 
the entire nine-month observation period.
The authors' conclusions
The primary purpose of opiate detoxification under general anaesthesia is to achieve a 
complete but quick and painless physical withdrawal. In this it generally succeeded. 
Patients typically exhibited only mild signs of withdrawal and required just one night in 
hospital, as reported by other studies. Propofol provides an excellent means of controlling 
excessive arousal of body systems caused by withdrawal, while clonidine allows for large 
doses of opioid antagonists to be delivered without significant changes in heart rate or 
blood pressure. The method used in the present study appears to be safe when 
performed by experienced anaesthetists and with round-the-clock care from qualified 
nursing staff for at least 24 hours.
Though this detoxification method ensures the initiation of long-term naltrexone 
treatment, its continuation might not depend on how the patient was withdrawn, but 
factors like ancillary drug use, family stability, and employment. The featured study's 
sample enjoyed relatively good personal and occupational situations and the close family 
support typical in Iran. Generally they did not inject, and were to a large extent free of 
official or legal pressure; voluntary detoxification is a positive prognostic feature in 
abstinence-oriented therapy. These factors might explain why 80% continued naltrexone 
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treatment for at least nine months, though retention on naltrexone does not always 
mean abstinence from opiate-type drugs.
Such results contrast with those of an Australian study, in which few patients completed 
nine months of naltrexone treatment after rapid withdrawal. In this study patients 
injected heroin and sometimes also abused alcohol, cannabis and benzodiazepines. 
[Editor's note: also half were unemployed, around 80% single, and generally they were 
poorly educated.]
Naltrexone significantly reduces relapse apparently only when rigorously supervised. New 
long-acting injectable or implantable formulations may address this limitation. But the 
featured study shows that in Iran, with patients generally not dependent on other drugs 
and with strong family as well as continuous medical support, oral naltrexone following 
rapid withdrawal can be sustained by most for many months.
Together with other studies, these findings suggest that not only the individual but also 
cultural and economic factors should be taken in to consideration. In Europe and North 
America rapid detoxification and naltrexone are not first-line detoxification treatments, 
not just because patients differ, but perhaps also because the health-care systems in 
those countries generally provide for the expensive option of inpatient detoxification over 
several days or weeks while doses of opiate-type drugs are gradually reduced to zero. 
 The authors of the featured study are appropriately cautious about 
generalising their findings beyond Iran and the type of patients they sampled, and the 
absence of a control group offered no treatment or an alternative means the results 
cannot securely be attributed to the studied treatment. However, with on average nearly 
ten years of opiate use behind them and still relatively young, it seems unlikely that the 
80% completion and abstinence rate reported by the study would have happened anyway 
without treatment. Another gap is what happened to the patients after treatment ended 
and they were no longer shielded by naltrexone which their families probably ensured 
they took.
Relevance to other countries
An obvious difference from Britain and many other countries is the dominance of non-
injecting routes of administration in Iran, but in recent years British drug users have also 
moved to non-injecting routes, an estimated 137,000 injectors in England in 2004/05 
falling to 117,000 in 2006/07. Estimates for England in 2009/10 were that of the 306,150 
opiate and/or crack users, just a third were injectors. These population trends fed in to 
the drug treatment system. By 2011/2012, just 18% of drug users starting treatment in 
England were recorded as currently injecting and over half – 55% – had never injected; 
in 2004–2005, the figures were 30% and 49% respectively. In Scotland the proportion of 
patients starting drug treatment who had injected in the previous month fell from 28% in 
2006/07 to 24% in 2010/11 and by more still in younger age groups with presumably 
shorter drug using careers. In particular, smoking or 'chasing' (inhaling fumes) opiates – 
generally heroin rather than opium – has long been established in Britain.
Notwithstanding national and caseload differences, the study reinforces indications that 
even in countries such as Britain and the USA, similar types of patients in similar 
circumstances can do well on oral naltrexone. The role of rapid withdrawal is to ensure 
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they at least start the procedure. Such patients include those committed to abstinence 
because considerable leverage is exerted over them by families, employers, professional 
bodies, or the criminal justice system, and can be exerted because the patients have 
much to lose (freedom, well paid jobs, reputations, careers, families, homes) by not 
complying. They also have the support and stability to be able to respond to that 
pressure by remaining in treatment and avoiding lasting relapse to opiate-type drugs.
Opiate blockers or substitutes?
For other types of patients, the majority in countries like Britain, rather than drugs which 
block opiates, the prescription of opiate-type drugs like methadone remains the mainstay 
of opiate addiction treatment (1 2). British guidelines relegate naltrexone to the minority 
of patients highly motivated to remain in an abstinence programme, contrasted with the 
more widespread applicability and more securely established effectiveness of substitute 
prescribing using methadone or buprenorphine. They also emphasise the need for anti-
relapse support after detoxification. More promising but not without their complications 
and controversies are long-acting forms of naltrexone placed under the skin as implants 
or injected. These have yet to be licensed for medical use in the UK, but some forms 
have been elsewhere.
The only study to have randomly allocated patients detoxified as inpatients to continuing 
treatment with oral naltrexone or with an opiate-type drug (buprenorphine) was 
terminated early when it became apparent that buprenorphine was clearly the best 
option. Supplementing counselling with naltrexone only slightly and non-significantly 
improved treatment retention and heroin use outcomes compared to a placebo. In 
contrast, outcomes were clearly and universally superior for the buprenorphine patients, 
significantly better than placebo, and generally also significantly better than naltrexone. 
Conducted in Malaysia, typically the patients were poorly educated single men with a 
history of imprisonment who had been using heroin for on average 15 years and had 
used near-daily in the previous month – a much less promising caseload than in Iran, 
adding weight to the proposition that such patients usually do better on drugs like 
buprenorphine and methadone.
Safety concerns
Among caseloads not endowed with substantial resources and on whom leverage is weak 
or ineffective, rapid relapse is the norm even after they have been able to complete 
detoxification; oral opiate blocking medication does little to improve the situation. 
Relapse brings with it what in some circumstances is a very high risk of death due to 
opiate overdose, because patients coming off naltrexone have entirely lost their tolerance 
to opiate-type drugs; the doses they used to take all too often prove fatal. Such concerns 
are less salient when opioids are taken by the much safer and controllable inhalation 
route.
It seems that with modern-day anaesthetic techniques and high quality care, rapid 
withdrawal procedures can be very safe. Nevertheless, due to safety concerns, British 
guidelines say the more radical of these procedures entailing (as in the featured study) 
anaesthesia or deep sedation "must not be offered", as in milder terms did guidelines 
published by the World Health Organization, though these did see a non-routine role for 
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procedures entailing minimal sedation. Similarly, a review for the Cochrane collaboration 
found that lighter forms of sedation ameliorate the severity of the withdrawal experience 
about as well as deep sedation or anaesthesia and are less risky. With no countervailing 
benefits but greater risk, the reviewers counselled against the more radical procedures.
For further discussion of these issues see this Findings hot topic on naltrexone implants and rapid detoxification, 
and earlier Findings analysis whose background notes (1 2) reviewed rapid withdrawal evidence to date. Other 
key sources are these Cochrane reviews on oral naltrexone and rapid withdrawal under heavy sedation or 
anaesthesia. For all relevant Findings analyses run these searches on naltrexone treatment for opiate addiction 
and on rapid withdrawal from opiate-type drugs.
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